Company Overview and News

77
ZTE, US suppliers shares tank after Senate puts Trump reprieve in doubt

15h malaymail
HONG KONG, June 20 — Shares of ZTE Corp and its American business partners took a hit yesterday after the US Senate's passage of a defence bill set up a potential battle with the White House over whether the Chinese telecoms firm can resume business with US suppliers.
FNSR XLNX ADI ACIA LITE QCOM

76
ZTE, U.S. suppliers shares tank after Senate puts Trump reprieve in doubt

2018-06-19 reuters
HONG KONG (Reuters) - Shares of ZTE Corp and its American business partners took a hit on Tuesday after the U.S. Senate’s passage of a defense bill set up a potential battle with the White House over whether the Chinese telecoms firm can resume business with U.S. suppliers.
FNSR XLNX ADI ACIA LITE QCOM

76
ZTE, US suppliers shares tank after Senate puts Trump reprieve in doubt

2018-06-19 channelnewsasia
Shares of ZTE Corp plunged on Tuesday after the U.S. Senate's passage of a defense bill set up a potential battle with the White House over whether the Chinese telecoms firm can resume business with its U.S. suppliers.
FNSR XLNX ADI ACIA LITE QCOM

27
ADI / Analog Devices, Inc. S-3ASR

2018-06-15 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 15, 2018 Registration No. 333-
ADI

27
ADI / Analog Devices, Inc. ANALOG DEVICES, INC. 8-K (Current Report)

2018-06-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
ADI

72
Texas Instruments: Well-Positioned In Growing Automotive Analog IC Market

2018-06-12 seekingalpha
Driven by rising EV/HEV and autonomous car sales, the automotive analog IC market is expected to be the fastest growing analog IC category over the next few years.
TXN ADI QCOM INTC MCHP MXIM ON

236
Dialog Semiconductor Plc: Distilling Risk From Uncertainty

2018-06-12 seekingalpha
Dialog is in the doghouse with investors. The stock price has fallen over 70% since its peak in March 2017 and over 40% just year to date.
TXN 6723 AAPL AVGO ADI NXPI RNECF DLGNF RNECY

71
Broadcom Shares On Pause, But The Business Isn't

2018-06-11 seekingalpha
Although weaker iPhone sales dented fiscal second quarter results, the business remains healthy overall and the wired business is set to accelerate.
QRVO AVGO ADI

27
Analog Devices: Estimates Could Be Too Low

2018-06-11 seekingalpha
As we get more clarity for when and how much 5G will impact Analog Devices' revenue, estimates for sales, earnings, and the stock are likely to be upgraded.
ADI

163
Top Research Reports for Facebook, Intel & Boeing

2018-06-01 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Intel (INTC) and Boeing (BA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
EIX WFCNP FB WFC.PRL WFC.PRJ CFIN WFC.PRT CHTR WFC.PRR WFC.PRQ WFC.PRP CIWV WFC.PRO WFC.PRN WFC.PRY INTC WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS DUKH DUK HUM PPG ADI LVS

49
Analog Devices, Inc. (ADI) Fundamental Valuation Report

2018-05-31 valuewalk
This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here.
SWKS TXN ADI ON MXIM

27
Analog Devices, Inc. (ADI) CEO Vincent Roche on Q2 2018 Results - Earnings Call Transcript

2018-05-30 seekingalpha
Good morning, and welcome to the Analog Devices Second Quarter Fiscal Year 2018 Earnings Conference Call, which is being audio webcast via telephone and over the web.
ADI LLTC

116
Analog Devices (ADI) Beats Q2 Earnings, Revenue Estimates

2018-05-30 zacks
Analog Devices Inc. (ADI - Free Report) reported second-quarter fiscal 2018 adjusted earnings of $1.45 per share, beating the Zacks Consensus Estimate by 8 cents. The bottom line surged 41% year over year and 3% sequentially. Also, the figure surpassed the guided range of $1.30-$1.44.
LFUS AMZN ADI

47
Amazon Roundup: Ad Tool, LatAm, Alexa, Whole Foods, TV, More

2018-05-30 zacks
It was an eventful few days at Amazon (AMZN - Free Report) with the company announcing its new ad tool, LatAm expansion plans, Whole Foods discounts for Prime, TV hire and more even as Alexa messed up.
511768 EXPE GRPN GOOGL MASTERTR TRIP ADI

69
DowDuPont's Unit to Sell Alginates Business to JRS Group

2018-05-30 zacks
DowDuPont Inc.’s (DWDP - Free Report) business unit, DuPont Nutrition & Health (N&H) has secured the green signal from the European Commission (EC) to divest its heritage DuPont N&H Alginates business to JRS Group that makes functional additives from plant-based raw materials. The transaction, which is expected to close in third-quarter 2018, includes the heritage DuPont N&H Alginates business, comprising pure and buffered alginates, a specific portfolio of pectin-alginate blends, the associated Landerneau production site and customer relationships.
FTI.WI ADI FMC CC DWDP CE

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ADI / Analog Devices, Inc. on message board site Silicon Investor.

Humble1 and Swing Trading Friends Canadian Political Free-for-All
Microcap Kitchen Canadian Stocks Media Industries: Newspapers, TV, Radio, Movies, Online
Canadian Diamond Play Cafi Underexposed Canadian Stocks
Canadian Oil u0026 Gas Companies Full Disclosure Trading
Canadian Warrants Only ClearStation...Goldman Sachs Trading Room in a Box?
CUSIP: 032654105